Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-ranging study of M610101 in non-segmental vitiligo
jRCT2031260035Phase 2Recruiting
- Sponsor
- Maruho Co., Ltd.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ruxolitinib cream in Vitiligo (4 arms), sponsored by Maruho Co., Ltd. Primary endpoint: F-VASI75 at Week 24. Started May 2026; status: recruiting.
02
Drugs
ruxolitinib cream
03
Conditions
Vitiligo
Beyond the preview
Go deeper on jRCT2031260035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260035.